Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 134Lung Neoplasms 50Adenocarcinoma of Lung 18Adenocarcinoma, Bronchiolo-Alveolar 10Brain Neoplasms 9NSCLC 8Neoplasms 5Neoplasm Metastasis 5Adenocarcinoma 4Respiratory Tract Diseases 3Carcinoma 3Thoracic Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Tongue Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Recurrence 1Previous Treated Metastatic Non-small Cell Lung Cancer 1Pleural Effusion, Malignant 1Parathyroid Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1

Interventions

Cisplatin 57Pemetrexed 46pembrolizumab 18Nivolumab 15Carboplatin 15Gemcitabine 14Cyclophosphamide 13Radiotherapy 10Drug Therapy 9atezolizumab 8Platinum 7Ipilimumab 7Doxorubicin 7durvalumab 61,2-diaminocyclohexaneplatinum II citrate 6tremelimumab 5sodium thiosulfate 5Vinorelbine 5Radiotherapy, Intensity-Modulated 5Interleukin-2 5Chemotherapy, Adjuvant 5Cerebral Decortication 5sargramostim 4fludarabine 4defactinib 4aldesleukin 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3cediranib 3Photochemotherapy 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Gefitinib × Thoracic × Clear all
NCT00025207 2013-01-17

Gefitinib in Treating Patients With Malignant Mesothelioma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00787410 2012-06-06

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

AstraZeneca

Phase 2 Completed
23 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡